JPH10503779A - フェノキシフェニル酢酸誘導体 - Google Patents

フェノキシフェニル酢酸誘導体

Info

Publication number
JPH10503779A
JPH10503779A JP8507425A JP50742596A JPH10503779A JP H10503779 A JPH10503779 A JP H10503779A JP 8507425 A JP8507425 A JP 8507425A JP 50742596 A JP50742596 A JP 50742596A JP H10503779 A JPH10503779 A JP H10503779A
Authority
JP
Japan
Prior art keywords
propylphenoxy
alkyl
isopropylbenzenesulfonyl
mmol
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP8507425A
Other languages
English (en)
Japanese (ja)
Inventor
バグレイ，スコツト・ダブリユ
ブローテン，セオドール・ピー
チヤクラバルテイー，プラサン・ケイ
ダノア，ダルジツト・エス
フイツチ，ケネス・ジエイ
グリーンリー，ウイリアム・ジエイ
ケビン，ナンシー・ジヨー
キーツイコウスキー，ジエラード・アール
マシユーズ，ジエイ・エム
ペテイボーン，ダグラス・ジエイ
リベロ，ラルフ・エイ
タタ，ジエイムズ・アール
ウオルシユ，トーマス・エフ
ウイリアムズ，デイビツド・エル，ジユニア
トウペンス，リチヤード・ビー
Original Assignee
メルク エンド カンパニー インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/294,232 external-priority patent/US5565485A/en
Application filed by メルク エンド カンパニー インコーポレーテッド filed Critical メルク エンド カンパニー インコーポレーテッド
Publication of JPH10503779A publication Critical patent/JPH10503779A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP8507425A 1994-08-08 1995-08-07 フェノキシフェニル酢酸誘導体 Pending JPH10503779A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US28737494A 1994-08-08 1994-08-08
US287,374 1994-08-08
US294,232 1994-08-22
US08/294,232 US5565485A (en) 1993-03-19 1994-08-22 Biphenyl compounds useful or endothelin antagonists
US47317295A 1995-06-07 1995-06-07
US473,172 1995-06-07
PCT/US1995/009967 WO1996004905A1 (fr) 1994-08-08 1995-08-07 Derives de l'acide phenoxyphenylacetique

Publications (1)

Publication Number Publication Date
JPH10503779A true JPH10503779A (ja) 1998-04-07

Family

ID=27403702

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8507425A Pending JPH10503779A (ja) 1994-08-08 1995-08-07 フェノキシフェニル酢酸誘導体

Country Status (4)

Country Link
EP (1) EP0774965A4 (fr)
JP (1) JPH10503779A (fr)
CA (1) CA2195758A1 (fr)
WO (1) WO1996004905A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005520858A (ja) * 2002-03-20 2005-07-14 メタボレックス， インコーポレイテッド 置換フェニル酢酸

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688974A (en) * 1995-12-12 1997-11-18 Merck & Co., Inc. Process for the preparation of an endothelin antagonist
WO1997021700A1 (fr) * 1995-12-12 1997-06-19 Merck & Co., Inc. Procede relatif a la fabrication d'un antagoniste de l'endotheline
WO1999048530A1 (fr) * 1998-03-23 1999-09-30 Merck & Co., Inc. Therapie combinee pour le traitement de l'hyperplasie prostatique benigne
US6410554B1 (en) 1998-03-23 2002-06-25 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
JPWO2010137336A1 (ja) * 2009-05-29 2012-11-12 興和株式会社 新規なα−フェノキシベンゼン酢酸誘導体及びこれを含有する医薬
CA2804593C (fr) 2010-07-09 2015-11-24 Pfizer Limited Derives de biphenyloxybenzensulphonamide utiles en tant qu'inhibiteurs du canal sodique
JP2013532184A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 電位開口型ナトリウムチャネル阻害剤として有用なｎ−スルホニルベンズアミド誘導体
CA2804351A1 (fr) 2010-07-12 2012-01-19 Pfizer Limited Composes chimiques
JP2013536165A (ja) 2010-07-12 2013-09-19 ファイザー・リミテッド 痛みの処置のためのｎａｖ１．７阻害薬としてのスルホンアミド誘導体
JP2013531030A (ja) 2010-07-12 2013-08-01 ファイザー・リミテッド 電位開口型ナトリウムチャネルの阻害剤としてのｎ−スルホニルベンズアミド
JP2013532185A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
WO2013088315A1 (fr) 2011-12-15 2013-06-20 Pfizer Limited Dérivés de sulfonamide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334598A (en) * 1993-03-19 1994-08-02 Merck & Co., Inc. Six-membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives
PT617001E (pt) * 1993-03-19 2000-06-30 Merck & Co Inc Derivados do acido fenoxifenilacetico
US5559135A (en) * 1994-09-14 1996-09-24 Merck & Co., Inc. Endothelin antagonists bearing pyridyl amides

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005520858A (ja) * 2002-03-20 2005-07-14 メタボレックス， インコーポレイテッド 置換フェニル酢酸

Also Published As

Publication number Publication date
CA2195758A1 (fr) 1996-02-22
EP0774965A1 (fr) 1997-05-28
WO1996004905A1 (fr) 1996-02-22
EP0774965A4 (fr) 1997-10-29

Similar Documents

Publication Publication Date Title
RU2139273C1 (ru) Производные феноксифенилуксусной кислоты
US5668176A (en) Phenoxyphenylacetic acid derivatives
US5538991A (en) Endothelin antagonists bearing 5-membered heterocyclic amides
WO1996009818A1 (fr) Antagonistes du recepteur d'endotheline utilises dans le traitement des vomissements
US5559135A (en) Endothelin antagonists bearing pyridyl amides
WO1995003044A1 (fr) Benzimidazolinones a substitution par des derives d'acide phenoxyphenylacetique
WO1994021255A1 (fr) Imidazoles fusionnes a anneau hexaedrique substitues par des derives d'acide phenoxyphenylacetique
RU2232751C2 (ru) Производные сульфонамидов и фармацевтическая композиция
JPH10503779A (ja) フェノキシフェニル酢酸誘導体
WO1994021259A1 (fr) Quinazolinones remplacees par des derives d'acide phenoxyphenylacetique
FR2903984A1 (fr) Derives d'imidazolones substitues, preparation et utilisations
AU683677B2 (en) Endothelin antagonists
US5767310A (en) Phenoxyphenylacetic acid derivatives
US6787559B2 (en) Sulfonamide compounds
AU705881B2 (en) Phenoxyphenylacetic acid derivatives
CA2361636A1 (fr) Utilisation d'amides d'acides pyrazol-carboxyliques
US12458624B2 (en) Deuterium-enriched substituted phenoxyphenyl acetic acids and acylsulfonamides